Health Canada moving to control chemicals used to make fentanyl

1 September 2016
canada-flag-big

Canada is experiencing a growing number of opioid overdoses and deaths across the country, and days such as the International Overdose Awareness Day are bringing needed attention to this crisis. The government of Canada is committed to addressing this complex public health issue.

The severity of this crisis in Canada requires that governments work together and move as fast as possible in order to confront the issue from all sides, stated the medicines regulator Health Canada.

As part of the federal government's commitment to take action to address the national opioid crisis, Health Canada is proposing to move forward with plans to restrict six chemicals used in the production of fentanyl, originally put forward by Senator Vern White's Senate Public Bill S-225, An Act to Amend the Controlled Drugs and Substance Act (substances used in the production of fentanyl). This regulatory proposal would achieve the intent of Senator White's Bill in an expeditious fashion, and add these substances to the Controlled Drugs and Substances Act (CDSA) and the Precursor Control Regulations (PCR), meaning that their unauthorized importation and exportation would be illegal.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical